Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Scott Ullem; Chief Financial Officer, Corporate Vice President; Edwards Lifesciences Corp Daveen Chopra; Corporate Vice President - Surgical Structural Heart; Edwards Lifesciences Corp Larry Wood ...

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in ...

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

Edwards Lifesciences Corp. closed 21.12% short of its 52-week high of $96.12, which the company reached on March 28th.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports.The firm currently has an ...

Q4 sales rose 9% year-over-year to $1.39B, beating the $1.36B consensus. Adjusted EPS of $0.59 topped estimates of $0.55. TMTT sales surged 77% in 2023 to $352M, driven by PASCAL and EVOQUE adoption.

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that ...